DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Lawitz E, Poordad F, Gutierrez JA. , et al.
SVR12 results from the Phase Ii, open-label .
IMPACT
study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and-experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease: 39.
Hepatology 2015;
62: 227A
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.